Pharmaceutical company Astex has entered an exclusive worldwide research agreement with Genentech to identify treatments for breast cancer. 

The partnership will aim to find small molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer, leveraging Astex’s fragment-based drug discovery programme. 

Under the terms of the agreement, Astex will grant Genentech, part of the Roche Group, an exclusive license to compounds from Astex’s existing drug discovery programme for breast cancer.   

Astex says it will collaborate with Genentech to accelerate the further optimisation and development of lead compounds towards the identification of preclinical candidates.  

Genentech will be solely responsible for preclinical and clinical development of lead candidates, as well as commercialisation of all medicines arising from the collaboration globally.  

Astex will receive an upfront payment of $25 million and is eligible to receive further milestone payments potentially totalling more than $490 million, as well as tiered royalties on net sales of medicines arising from the collaboration.    

“Working together with colleagues from Newcastle University, Astex’s fragment-based drug discovery expertise has led to the discovery of a novel and innovative approach to selectively inhibit this key oncology target for breast cancer therapy,” said Michelle Jones, President of Astex Pharmaceuticals. 

“Genentech’s focus on embracing innovation, its expertise in oncology and its longstanding dedication to innovation for breast cancer patients makes Genentech an excellent partner for this collaboration.  

“We are delighted to be working together in this important drug discovery alliance with the aim to build on our progress and accelerate compounds into development in a rapidly emerging area of need which, as yet, remains unmet.” 

“We are committed to pushing the boundaries of scientific innovation and turning breakthroughs into better outcomes for people with breast cancer,” added Boris Zaïtra, Head of Roche Corporate Business Development.  

“Working alongside partners like Astex Pharmaceuticals in pursuit of precision therapies against cell-cycle regulators, we follow the science to focus our innovation on the areas of the highest unmet need.”